Parkinsonism: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 2: Line 2:
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''
'''For patient information click [[{{PAGENAME}} (patient information)|here]]'''


{{SI}}
{{Parkinsonism}}
{{CMG}}
{{CMG}}
 
{{SK}} Parkinson's syndrome; atypical Parkinson's; secondary Parkinson's
==Overview==
==Overview==
'''Parkinsonism''' (also known as '''Parkinson's syndrome''', '''atypical Parkinson's''', or '''secondary Parkinson's''') is a neurological [[syndrome]] characterized by [[tremor]], [[hypokinesia]], [[spasticity|rigidity]], and [[balance disorder|postural instability]].<ref name=Aminoff_2005>{{cite book | author = Aminoff MJ, Greenberg DA, Simon RP | title = Clinical Neurology | publisher = Lange: McGraw-Hill Medical | edition = 6th ed. | pages = 241&ndash;5 |year = 2005 | isbn = 0071423605 }}</ref> The underlying causes of parkinsonism are numerous, and diagnosis can be complex.<ref>{{cite journal | author = Tuite PJ, Krawczewski K | title = Parkinsonism: a review-of-systems approach to diagnosis | journal = Seminars in neurology | volume = 27 | issue = 2 | pages = 113-22 | year = 2007 | pmid = 17390256 | doi = 10.1055/s-2007-971174}}</ref> While the [[neurodegenerative]] condition [[Parkinson's disease]] (PD) is the most common cause of parkinsonism, a wide-range of other [[Etiology|etiologies]] can lead to a similar set of symptoms, including some [[toxins]], a few [[metabolic disease]]s, and a handful of non-PD neurological conditions.<ref>{{cite journal | author = Christine CW, Aminoff MJ | title = Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance | journal = Am. J. Med. | volume = 117 | issue = 6 | pages = 412-9 | year = 2004 | pmid = 15380498 | doi = 10.1016/j.amjmed.2004.03.032}}</ref>  Its most common cause is as a side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol (Haldol)), piperazines (such as ziprasidone), and rarely, antidepressants.
'''Parkinsonism''' is a neurological [[syndrome]] characterized by [[tremor]], [[hypokinesia]], [[spasticity|rigidity]], and [[balance disorder|postural instability]].<ref name=Aminoff_2005>{{cite book | author = Aminoff MJ, Greenberg DA, Simon RP | title = Clinical Neurology | publisher = Lange: McGraw-Hill Medical | edition = 6th ed. | pages = 241&ndash;5 |year = 2005 | isbn = 0071423605 }}</ref> The underlying causes of parkinsonism are numerous, and diagnosis can be complex.<ref>{{cite journal | author = Tuite PJ, Krawczewski K | title = Parkinsonism: a review-of-systems approach to diagnosis | journal = Seminars in neurology | volume = 27 | issue = 2 | pages = 113-22 | year = 2007 | pmid = 17390256 | doi = 10.1055/s-2007-971174}}</ref> While the [[neurodegenerative]] condition [[Parkinson's disease]] (PD) is the most common cause of parkinsonism, a wide-range of other [[Etiology|etiologies]] can lead to a similar set of symptoms, including some [[toxins]], a few [[metabolic disease]]s, and a handful of non-PD neurological conditions.<ref>{{cite journal | author = Christine CW, Aminoff MJ | title = Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance | journal = Am. J. Med. | volume = 117 | issue = 6 | pages = 412-9 | year = 2004 | pmid = 15380498 | doi = 10.1016/j.amjmed.2004.03.032}}</ref>  Its most common cause is as a side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol (Haldol)), piperazines (such as ziprasidone), and rarely, antidepressants.


==Differential Diagnosis==
==Differential Diagnosis==

Revision as of 17:32, 15 May 2013

For patient information click here

Parkinsonism Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Parkinsonism from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parkinsonism On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parkinsonism

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parkinsonism

CDC onParkinsonism

Parkinsonism in the news

Blogs on Parkinsonism

Directions to Hospitals Treating Parkinsonism

Risk calculators and risk factors for Parkinsonism

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Synonyms and keywords: Parkinson's syndrome; atypical Parkinson's; secondary Parkinson's

Overview

Parkinsonism is a neurological syndrome characterized by tremor, hypokinesia, rigidity, and postural instability.[1] The underlying causes of parkinsonism are numerous, and diagnosis can be complex.[2] While the neurodegenerative condition Parkinson's disease (PD) is the most common cause of parkinsonism, a wide-range of other etiologies can lead to a similar set of symptoms, including some toxins, a few metabolic diseases, and a handful of non-PD neurological conditions.[3] Its most common cause is as a side effect of medications, mainly neuroleptic antipsychotics especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupenthixol and zuclopenthixol) and butyrophenones (such as haloperidol (Haldol)), piperazines (such as ziprasidone), and rarely, antidepressants.

Differential Diagnosis

If PD has been excluded, the differential diagnosis or list of potential causes for this syndrome includes:

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 Aminoff MJ, Greenberg DA, Simon RP (2005). Clinical Neurology (6th ed. ed.). Lange: McGraw-Hill Medical. pp. 241&ndash, 5. ISBN 0071423605.
  2. Tuite PJ, Krawczewski K (2007). "Parkinsonism: a review-of-systems approach to diagnosis". Seminars in neurology. 27 (2): 113–22. doi:10.1055/s-2007-971174. PMID 17390256.
  3. Christine CW, Aminoff MJ (2004). "Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance". Am. J. Med. 117 (6): 412–9. doi:10.1016/j.amjmed.2004.03.032. PMID 15380498.
  4. Tse W, Cersosimo MG, Gracies JM; et al. (2004). "Movement disorders and AIDS: a review". Parkinsonism Relat. Disord. 10 (6): 323–34. doi:10.1016/j.parkreldis.2004.03.001. PMID 15261874.
  5. Maltête D, Guyant-Maréchal L, Mihout B, Hannequin D (2006). "Movement disorders and Creutzfeldt-Jakob disease: a review". Parkinsonism Relat. Disord. 12 (2): 65–71. doi:10.1016/j.parkreldis.2005.10.004. PMID 16364674.
  6. Watanabe Y, Himeda T, Araki T (2005). "Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease" (PDF). Med. Sci. Monit. 11 (1): RA17–23. PMID 15614202.
  7. Wenning GK, Geser F (2003). "Multiple system atrophy". Rev. Neurol. (Paris). 159 (5 Pt 2): 3S31–8. PMID 12773886.
  8. Uc EY, Rodnitzky RL (2003). "Childhood dystonia". Seminars in pediatric neurology. 10 (1): 52–61. doi:10.1016/S1071-9091(02)00010-4. PMID 12785748.
  9. 9.0 9.1 9.2 DeLong MR, Juncos JL (2004). Parkinson's Disease and Other Movement Disorders. In: Harrison's Principles of Internal Medicine (16th ed. ed.). McGraw-Hill Professional. pp. p. 2414. ISBN 0-07-140235-7.
  10. Dinis-Oliveira RJ, Remião F, Carmo H; et al. (2006). "Paraquat exposure as an etiological factor of Parkinson's disease". Neurotoxicology. 27 (6): 1110–22. doi:10.1016/j.neuro.2006.05.012. PMID 16815551.
  11. Thanvi B, Lo N, Robinson T (2005). "Vascular Parkinsonism--an important cause of parkinsonism in older people" (PDF). Age and ageing. 34 (2): 114–9. doi:10.1093/ageing/afi025. PMID 15713855.
  12. Członkowska A, Tarnacka B, Möller JC; et al. (2007). "Unified Wilson's Disease Rating Scale - a proposal for the neurological scoring of Wilson's disease patients". Neurol. Neurochir. Pol. 41 (1): 1–12. PMID 17330175.

Template:WH Template:WS